Though we have tried to cover all companies yet on Sales and Potential in the Healthcare segment, we are really short staffed to push out first in class updates on the same. Suffice it to say that with Orchid Chem FCCB redemption coming up, bonds will be called and the fear has driven the scrip down from 186 levels.

Current TV18 interviews with promoter K Raghavendra Rao confirming that feears are misplaced as a further ECB has been ted up to return the earlier FCCB debt as also domestic arrangements have been made. The company is profitable with a 10% NPM and good Q_O_Q and year ly growth int he september quarter, running to $500mln + run rate Derfinitely no worth dropping and somethign you should buy and keep with Glenmark, Opto circuit (devices) and hold Biocon if you have any

Lupin and Cipla ar e the bigger ones in the area who were actively looking to sell out ahead of changing FDI regulation in the sector where earlier M&A has alreaydy sccooped out much local infrastructure and biggie Sun Pharma is adding inorganic marketing and research strengths. Dr Reddy is a stable business with sales intact a a $2 bln run rate

In most cases the domestic market is relatively small,  but that is more of a limitation for MNC pharma stocks still listed

Posted via email from The India Investment Post